



**FOR IMMEDIATE RELEASE**

**Media Contact:**

Shelley Parnell, VisionGate  
602.354.8222  
[parnell@visiongate3d.com](mailto:parnell@visiongate3d.com)

**VisionGate to Present at Leerink Partners Global Healthcare Conference**

PHOENIX, Ariz. (February 5, 2016) – VisionGate, Inc. today announced that the company will present at the Leerink Partners 5<sup>th</sup> Annual Global Healthcare Conference.

VisionGate Chairman & CEO Alan Nelson, PhD, will present at 1:50 p.m. EST on Wednesday, February 10, 2016 at the Waldorf Astoria in New York. Dr. Nelson will discuss VisionGate's recent acquisition of a chemoprevention drug for lung cancer. The new therapy will complement LuCED, the Company's diagnostic test to detect lung cancer at its earliest state – even precancerous cells – expanding the Company's portfolio and market reach.

For more information on VisionGate, please visit [www.visiongate3d.com](http://www.visiongate3d.com). To request a copy of the presentation following the conference, please email [parnell@visiongate3d.com](mailto:parnell@visiongate3d.com).

#

**About VisionGate**

VisionGate® is a commercial stage company focused on dramatically improving the diagnosis and treatment of lung cancer. The Company has a comprehensive offering that includes both a diagnostic platform to accurately detect lung cancer across all stages as well as a chemoprevention drug to treat dysplasia, or pre-cancerous cells, of the lung. LuCED®, its diagnostic test, is a physician-ordered, non-invasive sputum test with exquisite sensitivity and specificity across all lung cancer types and stages. LuCED is processed on the Company's proprietary, fully automated cell imaging platform, the Cell-CT®, which computes 3D cell images with sub-micron resolution and automatically identifies abnormal cells. LuCED's ability to detect lung cancer of all types and in all stages, including dysplasia, makes it a perfect companion to the Company's chemoprevention therapy, which demonstrated a 40% reduction in dysplasia in a successful Phase II National Cancer Institute-sponsored trial. With the combination of LuCED, a novel therapeutic and 131 issued patents worldwide, VisionGate expects to play a leading role in the battle against the world's number one cancer killer.